The Tolerability of the Dengue Vaccine TAK-003 (Qdenga®) in German Travelers: The Results of a Prospective Survey
Tomas Jelinek, Juliane Kramm, Maik Wagner, Claudia Jelinek, Ralph Huits · 2025
Read The Tolerability of the Dengue Vaccine TAK-003 (Qdenga®) in German Travelers: The Results of a Prospective Survey by Tomas Jelinek, Juliane Kramm, Maik Wagner, Claudia Jelinek, Ralph Huits (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12737764.txt.
Description
Jelinek and co-authors survey in a 2025 study how German travelers tolerated the dengue vaccine TAK-003 across its first two years on the market. A Berlin travel clinic gave over fifty-six thousand doses. Nearly twelve thousand vaccinees answered a questionnaire. Each had waited at least four weeks after the shot.
About half reported local reactions, mostly pain at the shot site, and about two fifths had body-wide ones like fatigue and muscle ache. Those usually started in the second week and lasted one to three days. A flat rash appeared in about a sixth. Among those who had since traveled to dengue lands, under one percent caught dengue, all mildly.
Catalog record
| CREATOR | Tomas Jelinek, Juliane Kramm, Maik Wagner, Claudia Jelinek, Ralph Huits |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |